Alexion Pharmaceuticals (ALXN) Lifted to "Outperform" at Robert W. Baird

Marco Green
January 14, 2018

More notable recent Alexion Pharmaceuticals, Inc. The stock decreased 0.81% or $0.375 during the last trading session, reaching $45.985. (NASDAQ:SFST) has risen 34.98% since January 12, 2017 and is uptrending. It has underperformed by 16.70% the S&P500.

According to Alexion Pharmaceuticals, Inc.'s latest 13F filing with the US Securities and Exchange Commission (SEC), institutional ownership is at 94.74%. Opus Point Partners Management Llc sold 23,553 shares as Alexion Pharmaceuticals Inc (ALXN)'s stock declined 11.63%.

Bridger Management Llc, which manages about $3.11 billion and $1.67B US Long portfolio, decreased its stake in Impax Laboratories Inc (NASDAQ:IPXL) by 738,687 shares to 602,456 shares, valued at $12.23 million in 2017Q3, according to the filing. Leerink Swann reissued an outperform rating and issued a $182.00 target price (up from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. The stock increased 0.25% or $0.31 during the last trading session, reaching $122.79. About 412,625 shares traded. (NASDAQ:ALXN) news were published by: which released: "Alexion and Elliott Agree to Collaborate on Identifying a New Board Member" on January 02, 2018, also with their article: "Oppenheimer Stays Bullish On Alexion Pharma" published on December 20, 2017, published: "Alexion Pharmaceuticals: A High Conviction, Large Cap Orphan Disease Pick For 2018" on January 08, 2018. One investment analyst has rated the stock with a sell rating, three have given a hold rating and twenty have issued a buy rating to the company's stock. Therefore 13% are positive.

Alexion Pharmaceuticals, Inc. has a consensus outperform rating from 21 Wall Street analysts, and the number of shares now sold short amount to at least 2.53% of shares outstanding. Wedbush maintained it with "Neutral" rating and $135 target in Friday, October 28 report. The original version of this piece of content can be accessed at As per Thursday, September 14, the company rating was maintained by Piper Jaffray. The firm has "Neutral" rating by BTIG Research given on Thursday, January 7. Goldman Sachs upgraded the shares of ALXN in report on Friday, October 28 to "Buy" rating. This public company's current market capitalization stands at $27.11 billion. The rating was maintained by BMO Capital Markets with "Market Perform" on Tuesday, August 29. Fort Washington Advisors Oh has 0.01% invested in Alexion Pharmaceuticals, Inc. It has outperformed by 18.44% the S&P500.

Analysts await Halozyme Therapeutics, Inc. (NASDAQ:ALXN) to report earnings on February, 15. ALXN's profit will be $241.29 million for 28.42 P/E if the $1.08 EPS becomes a reality. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.32 by $0.12. (NASDAQ:ALXN). Keybank Association Oh, Ohio-based fund reported 4,744 shares. 11,160 shares were sold by O'Neill Julie, worth $1.56M on Monday, August 28. Palo Alto Invsts Ltd Co invested in 6.38% or 1.08M shares. (NASDAQ:ALXN) was sold by HANTSON LUDWIG on Tuesday, January 2.

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.20, from 1.37 in 2017Q2. It turned negative, as 36 investors sold ALXN shares while 174 reduced holdings. 78 funds opened positions while 167 raised stakes. Geneva Advisors LLC grew its stake in shares of Alexion Pharmaceuticals by 0.7% during the second quarter. Conning stated it has 0.03% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). 2,078 are held by Mackenzie Finance. Lpl Financial Limited Liability Corp holds 25,253 shares. Amp Invsts Limited reported 88,361 shares. 2,280 are owned by Chicago Equity Prtn Ltd Liability Com. New York-based Secor Ltd Partnership has invested 0.18% in Halozyme Therapeutics, Inc. Balyasny Asset Management Ltd Liability Company invested 0.1% of its portfolio in Alexion Pharmaceuticals, Inc. Clough LP has invested 0.73% of its portfolio in Alexion Pharmaceuticals, Inc. It also reduced Applied Matls Inc (NASDAQ:AMAT) stake by 16,674 shares and now owns 53,904 shares. (NYSE:V). Benin Mngmt holds 125,641 shares or 5.33% of its portfolio.

Investors sentiment decreased to 1.17 in 2017 Q3. Its down 0.13, from 1.13 in 2017Q2. It is positive, as 32 investors sold UNFI shares while 70 reduced holdings. National Bank & Trust Of America Corp De has invested 0.01% in United Natural Foods, Inc. Commonwealth Equity Services invested in 7,544 shares. Natixis owns 74,267 shares for 0.1% of their portfolio. Financial Bank Of Nova Scotia owns 38,768 shares. (NASDAQ:ALXN). Moreover, Connor Clark And Lunn has 0.09% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:UNFI). Sei owns 18,767 shares or 0% of their U.S. portfolio. Stevens Management Limited Partnership stated it has 13,981 shares. Suntrust Banks holds 0.02% or 31,577 shares in its portfolio. Congress Asset Ma stated it has 39,028 shares. (NASDAQ:UNFI) for 187,652 shares.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, October 26th. During the same quarter in the prior year, the business earned $1.23 EPS. After $0.07 actual earnings per share reported by IAMGOLD Corporation for the previous quarter, Wall Street now forecasts -57.14% negative EPS growth.

Since October 19, 2017, it had 0 insider purchases, and 4 insider sales for $10.59 million activity. Veneman Ann M sold $121,751 worth of stock. There were 44 sold out positions, amounting to 1.89 million shares. (NYSE:V) shares were sold by MATSCHULLAT ROBERT W. 49,702 shares were sold by MAHON TULLIER KELLY, worth $5.65M on Friday, December 15. About 2.02M shares traded. 2,660 shares were sold by ROY PETER, worth $107,544. (NASDAQ:UNFI) or 11,500 shares. The Ithaka Group Llc holds 83,141 shares with $11.66 million value, down from 87,510 last quarter.

Other reports by Click Lancashire

Discuss This Article